XLIMUS®​

Sirolimus Eluting Coronary Stent System​

Unmatched deliverability and XLIMUS performance

XLIMUS®​

XLIMUS is considered as the ultimate coronary DES stent system to treat complex coronary artery disease by reaching and crossing the most challenging lesions.

01

XLIMUS is the ultimate coronary DES stent system to treat complex coronary artery disease by reaching and crossing the most challenging lesions.

02

XLIMUS offers a stable, flexible stent delivery system featuring a flexible tip technology allowing navigating the most tortous coronary anatomies

03

XLIMUS is a next generation thin stent strut Sirolimus DES, using the No. 1 drug which demonstrated long-term patient safety and optimal clinical efficacy, in more than 10.0 Million Patients.

Leading the future of
drug-eluting coronary stenting.

Source: Peter Smits,MD, from the COMPARE trial presentation at TCT 2009. *XLIMUS low metal volume stenting. Caution! Thinner struts, much below 71μm may influence stent stability.

Thin stent struts minimize foreign body metal volume.

XLIMUS reduces the inflammatory signal potential for prevention of late restenosis.

XLIMUS controlled biodegradable Sirolimus drug release.

XLIMUS ensures a controlled drug release after stent implantation.

No stent flaring. No tissue prolapse. Clinically effective.

Homogenous, clinically effective drug delivery optimizes the anti-proliferative protection of the stented lesion segment.

No stent strut flaring. No open gaps.

XLIMUS assists the cardiologist

XLIMUS®

A novel drug-eluting, cobalt chromium coronary stent system, which provides clinically effective antiproliferative, drug delivery to the coronary artery lesion to prevent restenosis, followed by a rapid functional endothelial healing.
 
  • Biodegradable Polymer
  • Sirolimus Drug Elution

Pulse Synchronous Stent Dynamics respond to coronary artery movement, with every heart beat. Natural stent flexion minimizes friction and shear stress to avoid vessel wall trauma. For a lifetime patient safety!

The highly biocompatible Poly (lactic acid) drug containing release matrix degrades smoothly and provides an optimal release kinetic profile. Within 30 days, about 70% of the anti-proliferative drug is distributed into the surrounding arterial tissue of the stent struts, ensuring a highly effective inhibition of smooth muscle cell migration and proliferation. Pharmacokinetic study result confirm sustained anti-proliferative drug efficacy up to 120 days.

The widest range of 72 stent sizes.

Stent
Length (mm)
2.25 mm2.50 mm2.75 mm3.00 mm3.50 mm4.00 mm4.50 mm5.00 mm
8 mmXL 2.25–8*XL 2.50–8*XL 2.75–8*XL 3.00–8*XL 3.50–8*XL 4.00–8*XL 4.50–8*XL 5.00–8*
12 mmXL 2.25–12XL 2.50–12XL 2.75–12XL 3.00–12XL 3.50–12XL 4.00–12XL 4.50–12*XL 5.00–12*
16 mmXL 2.25–16XL 2.50–16XL 2.75–16XL 3.00–16XL 3.50–16XL 4.00–16XL 4.50–16*XL 5.00–16*
20 mmXL 2.25–20XL 2.50–20XL 2.75–20XL 3.00–20XL 3.50–20XL 4.00–20XL 4.50–20*XL 5.00–20*
24 mmXL 2.25–24XL 2.50–24XL 2.75–24XL 3.00–24XL 3.50–24XL 4.00–24XL 4.50–24*XL 5.00–24*
28 mmXL 2.25–28XL 2.50–28XL 2.75–28XL 3.00–28XL 3.50–28XL 4.00–28XL 4.50–28*XL 5.00–28*
32 mmXL 2.25–32XL 2.50–32XL 2.75–32XL 3.00–32XL 3.50–32XL 4.00–32XL 4.50–32*XL 5.00–32*
36 mmXL 2.25–36XL 2.50–36XL 2.75–36XL 3.00–36XL 3.50–36XL 4.00–36XL 4.50–36*XL 5.00–36*
40 mmXL 2.25–40XL 2.50–40XL 2.75–40XL 3.00–40XL 3.50–40XL 4.00–40XL 4.50–40*XL 5.00–40*
Technical Data
MaterialCobalt Chromium Alloy L-605
Total strut thickness73µm (71µm Alloy + 2µm coating layer)
Coating layer2µm
Device lengthsStent length = balloon length = markers distance
Metal to artery ratio14% average
Nominal pressure8 ATM
Rated burst pressure16 ATM except diameters 4.5 / 5.0 and diameter 4.0 with length higher than 20mm (14 ATM)
Average foreshortening< 1%
Guiding catheter compatibility5F (0.058" ID) except diameters 4.5 and 5.0 —> 6F (0.071“)
Guidewire compatibility0.014" maximum recommended
Sirolimus (Rapamycin) drug-coating1.25µg/mm² stent surface

Interested with this product?

Scroll to Top